Innovative PolyStyreneLoop Plant Will Recycle Polystyrene Foam Demolition Waste and Recover Valuable Resources
A new recycling plant in the Netherlands will recycle expanded polystyrene (EPS) demolition waste and also handle a legacy additive.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005924/en/
An aerial view of the PolystyreneLoop recycling plant in Terneuzen, the Netherlands. (Photo: Business Wire)
The PolyStyreneLoop recycling plant in Terneuzen, Netherlands, is scheduled to open on the 16th of June. The plant was built to prove the technical and economic feasibility of a large-scale, closed-loop solution for the recycling of EPS waste.
The PolyStyreneLoop facility will recycle EPS insulation using a physical recycling process based on the CreaSolv® Technology. This technology will turn EPS foam demolition waste from building and construction insulation (B&C) from the Netherlands, Germany and other countries into new high quality raw material. All kinds of impurities, such as cement or other construction residues, as well as the legacy additive HBCD, will be safely removed and valuable bromine recovered.
“This plant showcases how the EPS industry is always looking for ways to boost its recycling capabilities,” said Lein Tange, Co-Director of PolyStyreneLoop. “The purpose of this plant is to pave the way for the construction of similar EPS recycling plants in the rest of Europe.”
The legal structure of the plant, which benefited from a European Union LIFE programme grant, was also unique. It has been built by the PolyStyreneLoop Cooperative, a Dutch non-profit organisation whose members comprise more than 70 industry representatives from the whole polystyrene foam value chain.
The Terneuzen plant will have the capacity to recycle 3,300 metric tonnes of polystyrene foam demolition waste coming from B&C per year, validating the technical, economic, and environmental viability of a new recycling process in which polystyrene foams containing HBCD can be fully integrated in the circular economy rather than being lost from circularity.
“It’s a real plus that the plant can not only take care of current recycling waste but also legacy recycling waste,” said Jan Noordegraaf, co-director of the plant. “Moreover, we can do this with about the same energy input as mechanical recycling and the energy we use comes solely from windmills.”
The PSLoop plant will demonstrate the possibility of infinite recycling of EPS B&C waste. Later, it will also recycle extruded polystyrene, or XPS, also known as StyrofoamTM.
EPS is a lightweight foam composed of 98% air and 2% technology with outstanding protective and thermal insulation properties. In addition to building and road construction uses, it is widely used in packaging to protect everything from heavy white goods to sensitive electronics, fresh fruit and vegetables, vaccines and even bees.
About PolyStyreneLoop
PolyStyreneLoop is a cooperative representing more than 70 companies from the polystyrene foam value chain. Its members include includes polystyrene raw material producers, foam manufacturers, additives suppliers, foam converters and recyclers as well as EUMEPS, the association and voice of European Manufacturers of Expanded Polystyrene.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005924/en/
Contact information
Lein Tange, Director
info@polystyreneloop.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release
Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom